Abstracts tagged "Disease Activity"

Abstract Number: 1972 • 2017 ACR/ARHP Annual Meeting
Causes of Death in 350 Patients with Systemic Autoimmune Rheumatic Diseases
Juan Gabriel Ovalles-Bonilla^1,2, Olaia Fernández-Berrizbeitia³, Julia Martínez-Barrio¹, Larissa Valor¹, Diana Hernández¹, Iustina Janta¹, Belen Serrano¹, Claudia Saez¹, Roberto Gonzalez¹, María Correyero¹, Leticia García¹, Ana López-Cerón¹, Alicia Silva¹, Juan Carlos Nieto¹, Carlos González^1,4, Indalecio Monteagudo¹ and Francisco Javier López Longo^1,4, ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ³Rheumatology, Hospital Universitario Basurto, Bilbao, Spain, ⁴Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: The major SARD have an increased mortality compared to the general population. It is well known that the main causes of death in Systemic…
Abstract Number: 2456 • 2017 ACR/ARHP Annual Meeting
Disease Flares Among Early Rheumatoid Arthritis Patients Treated with Continued Methotrexate Either Alone or in Combination with Adalimumab (Humira)
Arthur Kavanaugh¹, Ronald F van Vollenhoven², Prashanth Sunkureddi³, Ying Zhang⁴, Jessica L. Suboticki⁵ and Josef S. Smolen⁶, ¹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ²Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ³University of Texas Medical Branch, Galveston, TX, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc., Mettawa, IL, ⁶Division of Rheumatology, Department of Medicine, Medical University of Vienna, and Hietzing Hospital, Vienna, Austria
Background/Purpose : Some rheumatoid arthritis (RA) patients (pts) may experience flares in their disease even after reaching stable low disease activity (sLDA), but the consequences…
Abstract Number: 2820 • 2017 ACR/ARHP Annual Meeting
Disease Activity By the Sledai in Lupus Patients Who Self Report Sleep Disturbance and Sleep Impairment Using the Patient-Reported Outcomes Measurement Information System Instruments
Teresa Aberle¹, Rufei Lu², Sarah Cioli³, Stan Kamp¹, Wade DeJager¹, Stephen Apel⁴, Cristina Arriens⁵, Eliza Chakravarty⁶, Aikaterini Thanou¹, Joel M. Guthridge⁷, Joan T. Merrill⁸ and Judith A. James⁹, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Oklahoma Medical research af, Edmond, OK, ⁷Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, OKC, OK, ⁸Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Lupus patients commonly report sleep dysfunction, which is associated with upregulation of inflammatory cytokines in healthy people. Studies exploring relationships between self-reported sleep dysfunction…
Abstract Number: 435 • 2017 ACR/ARHP Annual Meeting
Characteristics of Rheumatoid Arthritis Patients Who Have a DMARD Interruption and the Impact of Using a Bridging Medication on Clinical and Patient Reported Outcomes
Christine Iannaccone¹, Michelle Frits², Taysir G. Mahmoud³, Gabriela Maica⁴, Jonathan Coblyn⁵, Michael Weinblatt² and Nancy A. Shadick⁶, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Department of Rheumatology, Allergy, and Immunology, Brigham and Women's Hospital, Boston, MA, ⁵Department of Rheumatology, Brigham & Womens Hospital, Boston, MA, ⁶Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: It is common for RA patients to interrupt their DMARD use due to events like infection, surgery, or pregnancy. Many RA patients may need…
Abstract Number: 921 • 2017 ACR/ARHP Annual Meeting
Discordant Patient-Physician Assessments of Disease Activity and Its Persistence Adversely Impact Quality of Life and Work Productivity in United States Hispanics with Rheumatoid Arthritis
George Karpouzas¹, Sera Ramadan², Chelsie Cost³, Taylor Draper⁴, Elizabeth Hernandez³ and Sarah Ormseth³, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Internal Medicine, Dignity Health St. Mary Medical Center, Long Beach, CA, ³Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁴Psychology, Loma Linda University, Loma Linda, CA
Background/Purpose: The impact of discordant patient-physician assessments of rheumatoid arthritis (RA) activity on quality of life is largely unknown. We examined the prevalence and stability…
Abstract Number: 1358 • 2017 ACR/ARHP Annual Meeting
Relationship between Serum Protein Pattern and High Disease Activity in Patients with Rheumatoid Arthritis
Pavel Horak¹, Anna Petráčková², Martina Skácelová³, Eva Kriegová⁴, Petra Schneiderová⁵ and František Mrázek⁵, ¹III. Department of internal medicine, III. Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacký University of Olomouc, Olomouc, Czech Republic, ²Department of Immunology, Department of Immunology, Faculty of Medicine and Dentistry, Palacky University of Olomouc, Olomouc, Czech Republic, ³III. Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacký University of Olomouc, Olomouc, Czech Republic, ⁴Department of Immunology,, Faculty of Medicine and Dentistry, Palacky University of Olomouc, Olomouc, Czech Republic, ⁵Department of Immunology, Faculty of Medicine and Dentistry, Palacky University of Olomouc, Olomouc, Czech Republic
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects joints. There is still limited information of serum biomarkers suitable for effective monitoring…
Abstract Number: 1624 • 2017 ACR/ARHP Annual Meeting
SLE Disease Activity Index Glucocorticosteroid Index (SLEDAI-2KG) Identifies More Responders Than Sledai-2K
Zahi Touma¹, Dafna D Gladman², Jiandong Su³, Nicole Anderson⁴ and Murray Urowitz⁴, ¹Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) is one of the most commonly used disease activity indices in clinical practice and research but this…
Abstract Number: 1992 • 2017 ACR/ARHP Annual Meeting
Changes in Clinical Disease Activity Are Associated with Changes in the Total MRI Inflammation Score in Rheumatoid Arthritis Patients Who Are Escalating Therapy in a Treat-to-Target (T2T) Regimen
Fiona M. McQueen¹, Peter T. Chapman², Terina Pollock³, Dena D'Souza⁴, Arier Lee⁵, Nicola Dalbeth⁶, Lisa K. Stamp⁷, Karen Lindsay⁸ and Anthony Doyle^3,9, ¹Molecular Medicine, Univ of Auckland Sch of Med, Auckland, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³Radiology, Auckland District Health Board, Auckland, New Zealand, ⁴Rheumatology, University of Auckland, Auckland, New Zealand, ⁵Biostatistics and Epidemiology, University of Auckland, Auckland, New Zealand, ⁶University of Auckland, Auckland, New Zealand, ⁷University of Otago, Christchurch, New Zealand, ⁸Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁹Anatomy with Radiology, University of Auckland, Auckland, New Zealand
Background/Purpose: RA patients are managed using treat-to target (T2T) regimens often utilizing the DAS28CRP as an outcome measure. In this study we compared clinical changes…
Abstract Number: 2485 • 2017 ACR/ARHP Annual Meeting
Outcomes of Switching from TNF Inhibitors to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events
Hiroki Wakabayashi¹, Hitoshi Inada², Yosuke Nishioka³, Masahiro Hasegawa^1,4, Kusuki Nishioka⁵ and Akihiro Sudo⁶, ¹Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, ²Orthopaedic Surgery, Suzuka General Hospital, Suzuka, Japan, ³Clinical Research Institute for Rheumatic Disease, Shima, Japan, ⁴Mie University Graduate School of Medicine, Tsu, Japan, ⁵Tokyo Medical University, Shinjuku, Japan, ⁶Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan
Background/Purpose: Tumor necrosis factor alpha (TNFα) inhibitors have been used to treat rheumatoid arthritis (RA) for >10 years. The outcomes has revolutionized the treatment goal…
Abstract Number: 2834 • 2017 ACR/ARHP Annual Meeting
Healthcare Cost Drivers in Rheumatoid Arthritis
Nina Mars¹, Anne M Kerola^2,3, Markku J Kauppi^4,5, Matti Pirinen¹, Outi Elonheimo⁶ and Tuulikki Sokka-Isler⁷, ¹Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, ²Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ³University of Helsinki, Helsinki, Finland, ⁴School of Medicine, University of Tampere, Tampere, Finland, ⁵Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁶FCG Finnish Consulting Group Ltd., Helsinki, Finland, ⁷Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Rheumatoid arthritis (RA) is associated with high healthcare resource utilization, but knowledge about factors determining healthcare costs is limited. The aim was to identify…
Abstract Number: 454 • 2017 ACR/ARHP Annual Meeting
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Correlates with Disease Activity in Early Rheumatoid Arthritis and Reflects Joint Damage over Time
Helena Enocsson¹, Alf Kastbom¹, Tanja Lukic¹, Christopher Sjöwall², Thomas Skogh¹ and Jonas Wetterö¹, ¹Rheumatology, Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, Linköping, Sweden, ²Department of Clinical and Experimental Medicine, Linköping University, Sweden, Linköping, Sweden
Background/Purpose: The urokinase plasminogen activator receptor (uPAR) is expressed on various cell types and plays important roles in proteolysis, migration and adhesion. Receptor shedding yields…
Abstract Number: 928 • 2017 ACR/ARHP Annual Meeting
Online Consultation for Chinese Patients with Rheumatic Diseases Based on Smart System of Disease Management (SSDM) Mobile Tool: A Study of Medical Economics
Fei Xiao¹, Rui Wu², Zhenchun Zhang³, Weiqi Min⁴, Yanchun Tang⁵, Xinwang Duan⁶, Lingfei Mo⁷, Zhaojun Guo⁸, Yanping Zhao⁹, Henglian Wu¹⁰, Xia Xu¹¹, Feng Jiang¹², Jing Yu¹³, Jianhong Qiang¹⁴, Yan Wang⁹, Ruijie Wu¹⁵, Anbing Zhang¹⁶, Limei Gu¹⁷, Hui Xiao¹, Yuhua Jia¹, Yuan Liu¹, Bing Wu¹, Chunhui Shi¹ and Fengchun Zhang¹⁸, ¹Gothic Internet Technology Corporation, Shanghai, China, ²The First Affiliated Hospital of Nanchang University, Nanchang, China, ³People's Hospital of Linyi, Shandong, Linyi, China, ⁴Heze Municiple Hospital, Heze, China, ⁵Yantai YuHuangDing Hospital, Yantai, China, ⁶Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁷The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China, ⁸The First People's Hospital of Huainan City, Huainan, China, ⁹First Affiliated Hospital of Harbin Medical University, Harbin, China, ¹⁰Dongguan Donghua Hospital, Dongguan, China, ¹¹Changhai Hospital, Shanghai, China, ¹²Huzhou Third People's Hospital, Huzhou, China, ¹³The First Hospital Affiliated with the University of Traditional Chinese Medicine in Liaoning Province, Shenyang, China, ¹⁴Yan'an People's Hospital, Yan'an, China, ¹⁵The Second Affiliated Hospital of Shanxi Medical College, Taiyuan, China, ¹⁶Xiangyang Central Hospital, Xiangyang, China, ¹⁷Central People's Hospital of Siping, Siping, China, ¹⁸Peking Union Medical College Hospital, Beijing, China
Background/Purpose: China doesn’t have efficient primary medical care and referral system. Patients can choose any hospitals or any doctors they like to seek medical care.…
Abstract Number: 1365 • 2017 ACR/ARHP Annual Meeting
Correlation of the Multi-Biomarker Disease Activity Score with Composite Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta-Analysis
Tate Johnson¹, Kyle A. Register², Cynthia Schmidt³, James R. O'Dell⁴, Ted R. Mikuls⁵, Kaleb Michaud¹ and Bryant R. England⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ³McGoogan Library of Medicine, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁵Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The regular assessment of disease activity is necessary to implement a treat-to-target management approach in RA. The Multi-Biomarker Disease Activity (MBDA) Score is a…
Abstract Number: 1629 • 2017 ACR/ARHP Annual Meeting
Disease Activity Is an Independent Predictor of Leukopenia in a Large International SLE Cohort
Rangi Kandane-Rathnayake¹, Vera Golder², Worawit Louthrenoo³, Sargunan Sockalingam⁴, Aisha Lateef⁵, Yuan An⁶, Leonid Zamora⁷, Yeong-Jian Wu⁸, Shue-Fen Luo⁹, Madelynn Chan¹⁰, Fiona Goldblatt¹¹, Chak Sing Lau¹², Zhan-Guo Li¹³, Sandra V. Navarra⁷, Mandana Nikpour¹⁴, Eric F Morand¹⁵ and Alberta Y. Hoi², ¹Rheumatology, Monash University, Melbourne, Australia, ²Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ³Division of Rheumatology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁴University of Malaya, Kuala Lumpur, Malaysia, ⁵Medicine, Division of Rheumatology, National University Hospital of Singapore, Singapore, Singapore, ⁶Peking University People's Hospital, Beijing, China, ⁷Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ⁸Chang Gung University, Taoyuan County, Taiwan, ⁹Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ¹⁰Tan Tock Seng Hospital, Singapore, Singapore, ¹¹Flinders University, Adelaide, Australia, ¹²Univ Dept of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ¹³Peking University International Hospital, Beijing, China, ¹⁴Melbourne University, Melbourne, Australia, ¹⁵Monash University, Melbourne, Australia
Background/Purpose: Leukopenia is commonly seen in SLE, but its predictors are not well understood, as it can be a result of disease activity or bone…
Abstract Number: 2143 • 2017 ACR/ARHP Annual Meeting
Circulating Endothelial Cells and Endothelial Activation Markers As Disease Activity Measures in Idiopathic Inflammatory Myopathies
Takayuki Kishi¹, Jonathan Chipman¹, Maryalice Stetler-Stevenson², Khanh Nghiem³, Melvina Evereklian¹, Margaret E. Rick³, Frederick W Miller¹ and Lisa G Rider¹, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ²Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, ³Coagulation Laboratory, Clinical Center, National Institutes of Health, Bethesda, MD
Background/Purpose: The idiopathic inflammatory myopathies (IIM) are systemic autoimmune diseases with chronic muscle inflammation and microvasculopathy of muscle and skin capillaries. Circulating endothelial cells (CECs),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].